Lv3
230 积分 2025-10-04 加入
The rationale for targeting the LOX family in cancer
3天前
已完结
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma
3天前
已完结
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
3天前
已完结
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
3天前
已完结
The biology and management of non-small cell lung cancer
3天前
已完结
LOXL2 in Epithelial Cell Plasticity and Tumor Progression
3天前
已完结
Lung cancer and epithelial-mesenchymal transition
3天前
已完结
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
4个月前
已完结
Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation
4个月前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
4个月前
已完结
皖公网安备34019202002308
